Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $105.00

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Moderate Buy” by the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $105.00.

Several research analysts recently commented on the stock. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target on the stock. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Guggenheim reissued a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Finally, Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd.

Insider Activity

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. The trade was a 20.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas Andrew Rowland sold 459 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the sale, the senior vice president directly owned 38,271 shares of the company’s stock, valued at $3,031,445.91. The trade was a 1.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 88,029 shares of company stock worth $6,954,472 in the last quarter. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Maryland State Retirement & Pension System lifted its position in ANI Pharmaceuticals by 5.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after acquiring an additional 134 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 143 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after acquiring an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after acquiring an additional 200 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its position in shares of ANI Pharmaceuticals by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after purchasing an additional 221 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $79.24 on Friday. The firm has a market capitalization of $1.80 billion, a PE ratio of 20.06 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The business has a 50-day moving average of $81.13 and a two-hundred day moving average of $79.52. ANI Pharmaceuticals has a 12 month low of $62.60 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the previous year, the company posted $1.70 EPS. The company’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts forecast that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.